Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
First subject dosed in Phase I study to evaluate safety and tolerability of…
Infex Awarded Biomedical Catalyst Grant For COV-X Project
Alderley Park, Cheshire, U.K - Infex Therapeutics, a leading anti-infectives…
COVID-19 Pandemic Triggers Upsurge in MBL Infections
New research has discovered that the ongoing COVID-19 pandemic has triggered a…
CARB-X Receives Additional $370m from U.S. Government and Wellcome
Enables continued investment in innovative projects to tackle the growing…
Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022…
Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism
Alderley Park, Cheshire - Infex Therapeutics, one of the UK’s leading…
Infex scientists achieve breakthrough to overcome critical priority drug resistant infections
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…
Infex agrees partnership with Colibri Scientific to provide services for RESP-X program
Alderley Park, Cheshire Infex Therapeutics has today announced a deal with…
Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…
Tackling underlying respiratory conditions for this pandemic and next
During the COVID-19 pandemic, one of the many phrases that has become…